ResMed (RMD) has investors’ attention after Q4 fiscal 2026 results showed 9% revenue growth and a 16% rise in non-GAAP EPS, alongside a richer capital return plan for fiscal 2027.
ResMed’s recent Q4 update has arrived after a mixed share price run, with a 90-day share price return of 18.37% but a year-to-date share price decline of 3.99% and a 1-year total shareholder return that is down 12.05%. The 3-year total shareholder return of 70.67% points to earlier momentum that is now being reassessed, as investors weigh the richer capital return plan against a 5-year total shareholder return that is down 5.46% at a latest share price of $235.04.
Scan how ResMed’s capital return push compares with other potential opportunities by reviewing our hand-picked 32 high quality undervalued stocks in the market today.
ResMed now trades at a meaningful discount to one set of fair value estimates and only a modest gap to analyst targets. Is the market’s caution after this mixed share price run mispricing the story, or is it keeping it honest?
Most Popular Narrative: 5.1% Undervalued
On the most followed view, ResMed’s fair value of $247.56 sits modestly above the last close at $235.04. This puts the recent Q4 beat and richer capital return plan into a valuation frame that assumes measured, not explosive, progress.
Supply chain productivity initiatives that have already widened gross margin by roughly 500 to 600 basis points in three years, combined with modest price increases and guidance for low double digit basis point margin improvement each year through 2030, point to an ongoing structural lift to gross margin and free cash flow.
See why 75 investors see ResMed as 5% undervalued.
Result: Fair Value of $247.56 (UNDERVALUED)
Still, the Astral field safety action and higher component and freight costs could pressure ResMed’s margins and test confidence in the current fair value story.
Find out about the key risks to this ResMed narrative.
Next Steps
If the mix of caution and optimism around ResMed leaves you undecided, move quickly and test the data against your own expectations, then see how that lines up with the 4 key rewards.
Looking for more investment ideas beyond ResMed?
If ResMed has sharpened your focus on pricing, cash flows, and risk, do not stop here. Broaden your watchlist now or risk missing easier wins nearby.
- Target resilience first and stress test your watchlist against market shocks with a focused set of 32 resilient stocks with low risk scores.
- Hunt for mispriced quality and compare ResMed with a curated pool of 32 high quality undervalued stocks that combine solid fundamentals with compressed expectations.
- Spot tomorrow’s quiet leaders early by scanning a tightly filtered group of 20 high quality undiscovered gems before broader attention arrives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com